OTLC News and Press, Oncotelic Therapeutics Inc From 12/14/21

--News Direct-- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical Officer and Board Director, Dr. Anthony Maida, will ...

The small cap biotech space offers a powerful dimension for active investors because it is comprised of stocks with little or no consistent correlation with the broad market, creating diversification without sacrificing explosive upside potential. But the group is best handled in baskets. In ...

With the spotlight firmly on Covid variants, it’s easy to lose sight of what will probably be the most important segment of the biopharma space over the next ten years: oncology. This is where the biggest success stories will be found. It’s where the largest revolutions will hap...

AGOURA HILLS, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that it has submitted clinical study...

We are increasingly seeing signs that the pandemic is hardly over. The European Union is battling record case levels. Areas of the US are starting to see some similar dynamics. Hospitals in the developed world are beginning to fill back up with Covid patients. It’s a familiar patt...

Mateon Therapeutics (OTCQB:OTLC): Q3 GAAP EPS of $0.00 beats by $0.01. Cash balance as of Sept. 30, 2021 of $0.08M Press Release For further details see: Mateon Therapeutics EPS beats by $0.01

AGOURA HILLS, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB: OTLC ) today announced financial results for the third quarter ended September 30, 2021 (“ Q3 2...

AGOURA HILLS, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that its COVID-19 trial (“C00...

The PD-1 blocker market has exploded into place as one of the most important and promising major biopharma oncology markets yet to appear. Immuno-oncology drugs that block the checkpoint PD-1 have been some of the most successful stories in the industry over recent years, launching blockbuste...

AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, provided an update on ongoing OT-101/IL-2 combination trial (the “Trial”...